Clinical Trial Update: Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial results for tipifarnib in relapsed or refractory peripheral T-cell lymphoma have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: Kura Oncology, Inc. | Conditions: Relapsed or Refractory Peripheral T-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-06-26